logo-loader
RNS
capAI PLC

capAI PLC - AGM Trading & Strategic Update

RNS Number : 2095B
capAI PLC
21 April 2026
 

THIS ANNOUNCEMENT ("ANNOUNCEMENT") AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE PROHIBITED BY ANY APPLICABLE LAW.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND ("UK") PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

21 April 2026


 capAI plc
 
(the "Company" and, together with its subsidiaries, the "Group" or "capAI")

AGM Trading & Strategic Update

capAI plc (LSE: CPAI, OTCQB: CPIQF) is pleased to provide a trading and strategic update ahead of its Annual General Meeting to be held today, Tuesday 21st April 2026.

 

The Company reports continued strong execution across its platform portfolio and is now entering a key inflection point, with multiple products transitioning from development into live user availability.

 

Near-Term Product Launches and Platform Momentum

 

·  Game42 (Going Live): Game42, the generative game creation platform, is scheduled to go live this week. Game42 enables users to transform inputs ranging from short prompts to full-length books into interactive game experiences, significantly lowering the barrier to game development and supporting scalable user-generated content ecosystems.

·   Creator42 / Movie42 (Going Live): Creator42, previously referenced in earlier communications, will launch this week under the name Movie42. The platform converts inputs-from a few lines to long-form narratives-into cinematic, trailer-style video outputs, positioning capAI within the rapidly expanding AI-driven content creation market.

·  Author42 (Hard Launch): The Company is progressing toward the hard launch of Author42, its AI-native writing platform. Author42 now includes expanded capabilities across fiction and memoir writing, alongside advanced editing and refinement tools, supporting end-to-end content creation and complementing the broader Game42 and Movie42 ecosystem.

 

Transition to Deployment and Commercial Evaluation

 

With Game42 and Movie42 entering live deployment, capAI is transitioning into a phase focused on user adoption, iterative improvement and commercial evaluation. These launches represent a significant step toward validating product-market fit across multiple verticals.

 

capMedical - Longevity and Healthcare Initiatives

 

Further to the Company's previous RNS announcements, capAI continues to progress its capMedical initiative, including its focus on AI-enabled longevity and healthcare applications. A number of potential programmes in this area remain under active evaluation, with the Company applying its disciplined venture approach to assess both scientific and commercial viability before committing further resources.

 

Disciplined Venture Structure (LOA Framework)

 

The Company has to date operated a disciplined venture model, typically securing opportunities through Licence and Option Agreements (LOAs) that provide optionality to acquire or license technologies developed in collaboration with R42.

 

This structure enables capAI to explore and develop multiple initiatives at relatively low cost, while retaining the ability to capture significant upside through option-based access to successful projects. By deferring major capital commitments until technical and commercial viability is clearer, the Company maintains capital discipline and reduces downside risk. However, shareholders should note that there can be no guarantee that the Company will ultimately exercise any option to acquire or license such projects. Decisions to proceed are made selectively, based on technical progress, market potential and capital allocation considerations.

 

Outlook

 

The capAI board believes that the transition of multiple platforms into live availability, combined with a growing pipeline of opportunities under evaluation, positions capAI for its next phase of growth. The Company remains focused on disciplined execution, capital efficiency and the selective advancement of high-potential initiatives.

 

Further updates will be provided in due course.

 

Commenting, Professor Ronjon Nag, Executive Chairman of capAI, said:

 

"We are now seeing the transition of our core platforms from development into live deployment, which is a critical step in validating both their technical capability and commercial potential.

 

"At the same time, we continue to apply our disciplined venture approach to the evaluation of new opportunities, including in AI-enabled longevity and healthcare, where we believe there is significant long-term value creation potential. We look forward to providing further updates as these initiatives progress."

 

For the purposes of UK MAR, the person responsible for arranging release of this Announcement on behalf of capAI is Professor Ronjon Nag, Executive Chairman.

 

Enquiries

 

Company:

capAI plc hello@capaiplc.com

 

Broker:

AlbR Capital Limited Tel: +44 (0) 207 469 0930

 

Important Legal Information

The information contained in this Announcement is for background purposes only and does not purport to be full or complete, nor does this Announcement constitute or form part of any invitation or inducement to engage in investment activity. No reliance may be placed by any person for any purpose on the information contained in this Announcement or its accuracy, fairness or completeness. The contents of this Announcement are not to be construed as legal, financial or tax advice.

 

This Announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefor.

 

This Announcement may include forward-looking statements, which are based on current expectations and projections about future events, including about the Group's operations, strategy, financial performance, development milestones, and the future prospects of its business divisions, including capMedia Inc, capMedical Inc, capMedia (UK) Ltd and capMedical (UK) Ltd. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "can have", "likely", "should", "would", "could" and any other words and terms of similar meaning or the negative thereof.

 

Forward-looking statements are based on current expectations and are subject to various risks and uncertainties that could cause actual outcomes to differ materially. These risks include, but are not limited to: successful execution of definitive agreements; regulatory approvals; development timelines; market acceptance; technological shifts; and broader economic conditions. No representation or warranty is made or will be made that any forward-looking statement will come to pass, and no assurance can be given that any forward-looking statement will prove accurate. Except as required by law, capAI undertakes no obligation to revise or update any forward-looking statement. The forward-looking statements in this Announcement speak only as at the date of this Announcement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEAELEADSKEAA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

6 min read